Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus
Article
[키워드] 1:1
3CL
3CL Protease
Acetate
activity
acute respiratory syndrome
addition
Antiviral
binding affinity
carried
cause
cellular
characterization
China
Clinical efficacy
clinical study
complex
component
Concentration
coronavirus
Coronavirus replication
COVID
COVID-19
COVID-19 pandemic
criteria
docking
Efficacy
epithelial cell
evaluate
factorial design
Factors
FDA-approved drugs
Glatiramer acetate
half-maximal inhibitory concentration
Health
IC50
investigated
Nanoparticles
outbreak
Prevent
protease
protease inhibition
required
responses
SARS-CoV-2
selected
shown
sitagliptin
target cell
TEM
the SARS-CoV-2 virus
transmission electron microscopy
treat
VERO-E6
virus
were assessed
[DOI] 10.3390/ph14030178 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/ph14030178 PMC 바로가기 [Article Type] Article